LRRK2 and Parkinson disease: We further illustrate that the mtDNA damage phenotype can be restored by pharmacological treatments with both selective and non-selective LRRK2 inhibitors in LRRK2 cellular models and G2019S LRRK2 PD patient-derived cells.